Colin Love - Replimune Chief Officer
| REPL Stock | USD 13.26 1.67 11.19% |
Executive
Dr. Colin Love, Ph.D., is Chief Operating Officer of the Company. He was a member of the board of directors of Replimune Limited since July 2017. Following the acquisition of BioVex by Amgen in 2011, Dr. Love remained at Amgen as Vice President of Clinical Operations, working on TVec until it was approved in 2015. Since 2014, Dr. Love has also provided consulting support to biotechnology companies through Clove Consulting Ltd. From 2000 until it was acquired in 2011, Dr. Love served as Senior Vice President of Product Development at BioVex
| Age | 66 |
| Professional Marks | Ph.D |
| Address | 500 Unicorn Park Drive, Woburn, MA, United States, 01801 |
| Phone | 781 222 9600 |
| Web | https://www.replimune.com |
Replimune Management Efficiency
The company has return on total asset (ROA) of (0.2707) % which means that it has lost $0.2707 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5032) %, meaning that it created substantial loss on money invested by shareholders. Replimune's management efficiency ratios could be used to measure how well Replimune manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.46. The value of Return On Capital Employed is expected to slide to -0.55. At this time, Replimune's Net Tangible Assets are quite stable compared to the past year. Debt To Assets is expected to rise to 0.10 this year, although the value of Total Assets will most likely fall to about 359.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Deborah JD | Nuvalent | 48 | |
| JD Esq | Kura Oncology | 53 | |
| Scott Holmes | Ascendis Pharma AS | N/A | |
| Asif Ali | Protagonist Therapeutics | 50 | |
| Matthew Gosling | Protagonist Therapeutics | 53 | |
| Francis Burrows | Kura Oncology | N/A | |
| Wes Trotter | Kronos Bio | N/A | |
| Steve Sabus | Syndax Pharmaceuticals | 57 | |
| Matt Cravets | Gossamer Bio | N/A | |
| Susan Fischer | Aerovate Therapeutics | N/A | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
| Douglas Kling | NewAmsterdam Pharma | 51 | |
| Jeffrey Fellows | Mineralys Therapeutics, Common | N/A | |
| Richard MD | Lyra Therapeutics | 61 | |
| MPH DO | Kronos Bio | 59 | |
| III JD | PureTech Health PLC | N/A | |
| Stephen Yu | Aerovate Therapeutics | N/A | |
| Ashley PharmD | Merus BV | N/A | |
| Barbara JD | Kronos Bio | 65 | |
| Allison JD | Kronos Bio | 41 | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.27 |
Replimune Group Leadership Team
Elected by the shareholders, the Replimune's board of directors comprises two types of representatives: Replimune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Replimune. The board's role is to monitor Replimune's management team and ensure that shareholders' interests are well served. Replimune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Replimune's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Coffin, President CEO, Director | ||
| Sushil Patel, Chief Officer | ||
| Colin Love, Chief Officer | ||
| Christopher Sarchi, Chief Officer | ||
| Tanya MS, Chief Officer | ||
| Philip FSA, Executive Chairman | ||
| Pamela Esposito, Chief Business Officer | ||
| Emily Hill, Chief Officer | ||
| Paul Bullock, Chief Head | ||
| Andrew Schwendenman, Chief Treasurer | ||
| MBA MD, Chief Officer | ||
| Jean Franchi, CFO, Officer |
Replimune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Replimune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 665.54 M | ||||
| Shares Outstanding | 68.42 M | ||||
| Shares Owned By Insiders | 4.71 % | ||||
| Shares Owned By Institutions | 95.29 % | ||||
| Number Of Shares Shorted | 7.05 M | ||||
| Price To Book | 2.68 X | ||||
| EBITDA | (230.2 M) | ||||
| Net Income | (215.79 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.